Equities Analysts Set Expectations for BIO Q4 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research reduced their Q4 2025 earnings estimates for Bio-Rad Laboratories in a research report issued to clients and investors on Wednesday, December 18th. Zacks Research analyst R. Department now expects that the medical research company will earn $3.21 per share for the quarter, down from their prior estimate of $3.28. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2026 earnings at $3.16 EPS.

Several other brokerages have also weighed in on BIO. Citigroup increased their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Royal Bank of Canada lifted their price objective on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a research report on Monday, December 9th. Finally, Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 target price for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $394.20.

Bio-Rad Laboratories Trading Up 0.3 %

Shares of NYSE BIO opened at $328.36 on Monday. Bio-Rad Laboratories has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a market cap of $9.19 billion, a price-to-earnings ratio of -12.01 and a beta of 0.90. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock’s 50 day simple moving average is $340.72 and its 200 day simple moving average is $322.85.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same quarter in the prior year, the business earned $2.33 earnings per share. Bio-Rad Laboratories’s quarterly revenue was up 2.8% on a year-over-year basis.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after purchasing an additional 45 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories in the third quarter valued at $32,000. Headlands Technologies LLC bought a new position in Bio-Rad Laboratories during the second quarter valued at about $51,000. Point72 Hong Kong Ltd acquired a new position in Bio-Rad Laboratories during the third quarter worth about $55,000. Finally, Quarry LP bought a new stake in Bio-Rad Laboratories in the second quarter worth about $59,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.